Are some groups more likely to get Keytruda (pembrolizumab) side effects?
Keytruda’s side effects come largely from immune system activation, so risk is not limited to a single diagnosis. People can experience immune-related side effects in various organs (for example, thyroid, lungs, colon, liver, skin, and others). In general, the likelihood and severity of immune-related adverse events can be influenced by baseline health and certain medical factors, but the exact “more at risk” group can vary by the specific side effect.
Which pre-existing conditions can raise risk of serious immune side effects?
Patients with autoimmune or immune-mediated disorders are commonly treated with extra caution with checkpoint inhibitors like Keytruda. The concern is that activating the immune system may worsen underlying autoimmune disease or trigger immune flares. That risk pattern is most relevant to side effects that mimic or overlap with autoimmune inflammation (for example, colitis, hepatitis, pneumonitis, and other immune-mediated organ inflammation).
People with significant organ dysfunction (such as impaired liver or lungs) may also face higher stakes if an immune reaction develops, even if the underlying “risk” of getting the side effect is not precisely quantifiable without more patient-level data.
Does age, race, or sex affect Keytruda side-effect risk?
Trial and real-world experience with immunotherapies often show that older adults can be more vulnerable to complications from immune toxicities and from treatment interruptions, even when side-effect rates may not be dramatically different across age groups. Sex and other demographic factors can influence immune responses in complex ways, but there is no single simple rule that one demographic is always more likely to get Keytruda side effects than another.
Are people with prior transplants or chronic immunosuppression at higher risk?
Patients who have had organ transplants are at particular risk because immune activation can threaten graft survival. Chronic immunosuppression and immune-modifying therapies can also affect how safe and effective checkpoint inhibitors are for an individual.
For people taking immunosuppressive drugs for other reasons, clinicians often weigh risks carefully because these medicines can both (1) complicate immune-related toxicity management and (2) change treatment effectiveness.
Which side effects tend to be “higher risk” in specific patient populations?
The “who is more at risk” question is usually most actionable when tied to a specific toxicity type:
- Immune-mediated diarrhea/colitis: higher concern if the person has a history of inflammatory bowel disease or other chronic gut inflammation.
- Immune-mediated hepatitis: higher concern if the person has chronic liver disease or baseline liver enzyme abnormalities.
- Immune-mediated lung inflammation (pneumonitis): higher concern if the person already has significant lung disease or prior lung radiation.
- Endocrine effects (thyroid disorders, adrenal issues, diabetes-related changes): risk may be influenced by baseline endocrine status, though new immune endocrinopathies can occur in anyone.
- Severe skin reactions: risk is not confined to a single subgroup, but a patient’s history of severe drug reactions can matter.
What should patients and caregivers watch for, regardless of risk group?
Even if risk varies, immune side effects can become serious quickly. Patients on Keytruda should report new or worsening symptoms such as shortness of breath or cough, persistent diarrhea or abdominal pain, yellowing of the skin/eyes, severe rash or blistering, severe fatigue with weakness or dizziness, severe headaches or confusion, or sudden changes in blood sugar—promptly, so clinicians can evaluate and stop or treat toxicity early when needed.
What determines “more risk” for your situation?
Clinicians tailor risk assessment to the individual using details like:
- whether the patient has autoimmune disease (and how severe),
- prior transplant status,
- underlying lung or liver conditions,
- baseline organ function,
- current medications (especially immunosuppressants),
- prior radiation and cancer treatment history.
If you share the patient’s cancer type and any relevant medical history (autoimmune disease, transplant, chronic lung/liver conditions, current meds), I can map which Keytruda toxicities are most clinically expected in that context and what symptom patterns usually trigger urgent evaluation.
Sources
No sources were provided with the question, so I can’t cite specific Keytruda label or guideline claims here. If you want, paste the relevant Keytruda prescribing information section (Warnings/Precautions or adverse events) or a link you’re using, and I’ll summarize which subgroups are identified there as higher risk and for which side effects.